Skip to content
Peptigraph home

GLP-1 Pipeline Tracker

The weight-loss and metabolic drugs after semaglutide and tirzepatide: who makes them, how far along they are, and their US status. Each entry links to its dated milestones.

Pipeline

16 drugs tracked

GLP-1 and related drugs in development
DrugClassSponsorPhaseUS status
RetatrutideGLP-1/GIP/glucagon triple agonistEli LillyPhase 3Investigational · phase 3 (TRIUMPH)
OrforglipronOral small-molecule GLP-1Eli LillyApprovedFDA approved as Foundayo (1 Apr 2026)
CagriSemaAmylin + GLP-1 combinationNovo NordiskPhase 3Investigational · filed with FDA
CagrilintideAmylin analogNovo NordiskPhase 3Investigational (CagriSema component)
SurvodutideGLP-1/glucagon dual agonistBoehringer IngelheimPhase 3Investigational · phase 3
MazdutideGLP-1/glucagon dual agonistInnovent Biologics; Eli LillyPhase 3Approved in China; investigational in the US
AmycretinGLP-1/amylin unimolecular agonistNovo NordiskPhase 3Investigational
MariTideGLP-1 agonist / GIPR antagonist antibody-peptideAmgenPhase 3Investigational
EloralintideAmylin agonistEli LillyPhase 3Investigational
PemvidutideGLP-1/glucagon dual agonistAltimmunePhase 3 (MASH)Investigational
VK2735GLP-1/GIP dual agonistViking TherapeuticsPhase 3Investigational
PetrelintideAmylin analogZealand Pharma / RochePhase 3 (registered, not yet recruiting)Investigational
EcnoglutideGLP-1 agonistHangzhou Sciwind BiosciencesPhase 3Investigational
EfinopegdutideGLP-1/glucagon dual agonist (MASH)Merck Sharp & DohmePhase 2Investigational
DapiglutideGLP-1/GLP-2 dual agonistUniversity Hospital, Gentofte, CopenhagenPhase 2Investigational
BimagrumabActivin receptor antibody (muscle-sparing)Eli Lilly (earlier trials: Novartis)Phase 2 (obesity)Investigational

Phase and sponsor come from public company and regulator records. Bracketed values are pending a source.